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Abstract: Statins, a group of potent inhibitors of 3-hydroxy-3-methylglutaryl Coenzyme A 
reductase in cholesterol biosynthesis pathway, have been widely used as a cholesterol 
lowering drug. The plieotrophic effect of statins on bone metabolism in long-term usage 
has been begun to be studied during recent years and several in vitro and in vivo studies 
have demonstrated the ability of statins to promote expression of bone morphogenetic 
protein-2 (BMP-2), inhibition of osteoclast differentiation and reduction of osteoporotic 
fractures risk. The high liver specificity and low oral bioavailability of statins, leading to 
poor peripheral distribution, are the main obstacles to benefit anabolic effects of 
hydrophobic statins on bone formation. Therefore, developing new administration roots for 
direct delivery to achieve optimum concentration in the bone microenvironment is of 
interest. Here we present and compare two approaches of combining statins with bone 
tissue engineering scaffolds. Simvastatin was combined with a poly(lactide-co-glycolide) 
(PLGA) membrane scaffold for diffusion-controlled release by dissolving simvastatin  
(dis-sim) in the membrane casting dope, and for degradation-controlled release by 
covalently bonding saponifiedsimvastatin (sap-sim) to the PLGA in the spinning dope. 
Rheological and concentration-dependent membrane morphology changes were observed 
with saponifiedsimvastatin, suggesting ester bond cleavage and covalent bonding of the 
statin to the PLGA, but not with dissolved simvastatin. Dissolved simvastatin membranes 
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showed a logarithmic decay release profile while the saponifiedsimvastatin membranes 
showed constant release. It can be concluded that the covalent bonding of  
simvastatinto PLGA scaffolds is showing potential for use as a controlled releasescaffold 
for bone tissue engineering. 
Keywords: PLGA; membrane; scaffold; statin; controlled release; bone tissue engineering  
 
1. Introduction 
More than one in three women and one in ten men suffer from osteoporosis over a lifetime, with a 
fracture risk of up to 40% in women and 13–25% in men [1]. Osteoporosis is the most common 
debilitating skeletal disorder, characterized by declining quality and quantity of cancellous and cortical 
bone [1]. The compounds that are currently available for the treatment of osteoporosis are mainly 
limited to anti-resorptive drugs such as calcitonin, estrogen, selective estrogen receptor modulators, 
biphosphonates, calcium supplementation and ipriflavone. Anti-resorptive drugs inhibit osteoclast 
activity and decrease bone turn over but lack anabolic effect with a very weak to moderate effect on 
elevation of bone mineral density (BMD) which decreases to less than 50% in advance stages of 
osteoporosis. Parathyroid hormone (PTH), sodium fluoride and strontium ranelate are few candidates 
currently under investigation with anabolic effects on bone metabolism, however their therapeutic 
application faces number of issues of concern [1]. In addition to some gastrointestinal side effects, the 
result of using fluoride in clinical trials were not encouraging despite its initial promise [2,3]. Apart 
from cost, root of administration, dosage regimen and its long-term effect on bone are questions that 
need to be answered before using PTH as bone anabolic agent in the clinic [1]. Strontium ranelate is 
another compound currently under investigation with bone anabolic effects and has shown a dual 
action on bone metabolism by reduction of bone resorption and stimulation of bone formation both  
in vitro [2] and in vivo [3]. 
A group of drugs called statins were introduced as cholesterol-reducing drugs but have  
been found to increase bone mass [4–6]. Statins are irreversible and competitive inhibitors  
of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase that initially acts by displacing the 
natural substrate (HMG-CoA) in the cholesterol biosynthetic pathway, reducing biosynthesis of 
mevalonate and consequently cholesterol in a dose-dependent manner [1,7]. Some beneficial effects of 
statins are related to their hypocholesterolemic property and inhibition of HMG-CoAreductase such as 
prevention of arthrosclerosis. However, other beneficial effects related to administration of statins have 
been reported that are not in direct relation with cholesterol reduction, a phenomenon known as a 
pleiotropic effect. Amongst the various pleiotropic effects of statins, their anabolic effect on bone 
metabolism, reported for the first time in 1994, has recently been receiving attention. Although the 
exact molecular mechanism of increase in bone formation remains elusive [1], the collected in vitro 
and in vivo evidence supports the notion that stimulation of vascular endothelial growth factor  
(VEGF) [8] and bone morphogenic protein-2 (BMP-2) due to possible inactivation of functional 
prenylated small GTPase produced in the mevalonate pathway is responsible for the anabolic effects of 
statins on bone metabolism [6,9–11]. In vitro induction of osteogenesis on a non-transformed 
Polymers 2010, 2 
 
 
711
osteoblast (MC3T3-E1) with simvastatin revealed that induction of BMP-2 expression and enhancing 
alkaline phosphatase activity and mineralization take place in a dose- and time-dependent manner [11]. 
In addition, anti-resorptive properties and inhibition of osteoclast formation have been attributed to the 
statins in a number of studies [4,12]. In contrast to in vitro studies which all affirm the anabolic and 
anti-resorptive effects of statin in bone metabolism, the results of in vivo studies have been 
controversial. While a number of studies using subcutaneous and oral administration of mainly 
lipophilicstatins have claimed a significant increase in new bone formation in normal and 
ovariectomizedrats [13,14], others have found more controversial results, indicating a lack of  
anabolic effects on bone formation [15,16] and an increase in bone turnover and decrease in bone 
formation [17]. It has been suggested that poor absorption of statins (less than 5% of an oral dose), 
high hepatic selectivity and first-pass effect cause a low systemic and peripheral concentration of 
statins following by oral administration [1,14]. Consequently, osteoblasts and osteoclasts exposed to a 
very low concentration of statins which might not be sufficient for their alteration, indicate that oral 
administration is not an ideal delivery method to benefit possible anti-osteoporotic property of  
statins [1] while significant increase in new bone formation was seen following topical [18,19], 
subcutaneous [4] and direct injection into the bone marrow cavity [20] compared to oral 
administration. New techniques for the administration of statins, for promotion of osteogenesis, have 
utilisedstatin-embedded polymers, manifesting significant positive effects on bone formation [21–24]. 
Although the effect of statins, especially the lipophilic derivatives on elevation of BMP-2, increase of 
ALP activity and promotion of osteogenesis have been proven in numerous studies, little has been 
done to capitalize on their effect by developing a suitable scaffold (a biomaterial that can be used to 
implant into a patient defect) for promotion of osteogenesisin vitro. In addition, scaffolds can be used 
as suitable delivery devices to overcome low concentration of statins in peripheral blood circulation 
necessary for anabolic effect on bone metabolism by delivering the drug locally. Scaffolds are highly 
porous structures which provide a three-dimensional support for cell attachment, proliferation and 
differentiation [25] to ultimately aid regeneration of an injured site. Polymer structures have been 
widely used to develop new controlled release drug delivery devices and devising such a drug delivery 
device to deliver statins to the site of injury at the desirable local drug concentration is necessary to 
fully utilize the anabolic effects of statins. The in vitro effect of statins on formation of bone have been 
known for more than half decade, however it is only recently that two polymer-based biomaterials 
have been developed by grafting simvastatin into the PLGA using oxalyl chloride chemical  
reaction [20] and incorporating fluvastatin into poly(ethanol glycol) based hydrogel [26]. In order to 
develop new controlled release systems to be used in bone tissue engineering, grafting statins  
into polymer via covalent bonds is ideal to achieve a degradation-dependant release instead of a  
diffusion-dependant release, characteristic of drug-blended polymers.  
Simvastatin is currently the most commonly prescribed statin in the UK and is available for 
purchase in a pharmacy without prescription. It has been shown that simvastatin significantly  
up-regulates osteoblast differentiation and extracellular matrix production [11].  
We are investigating the approach of combining simvastatin covalently with poly(lactide-co-glycolide) 
(PLGA) to develop a controlled release system for simvastatin, in a biocompatible and degradable 
polymer that is suitable for implantation into bone tissue. PLGA has a long history of safe and 
effective clinical use.Using PLGA to support and guide a wound healing response in a bone defect is a 
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therapeutic option. Combining PLGA with a bone-stimulating molecule such as simvastatin could 
greatly enhance the local physiological repair mechanism. This paper outlines a method to covalently 
attach simvastatin to PLGA using saponificationand describes our results on the subsequent controlled 
release patterns. 
2. Experimental Section 
2.1. Materials 
Poly(D,L-lactide-co-glycolide), having a lactide:glycolide molar ratio of 75:25, (PLGA) was 
purchased from BoehringerIngelheim (RG756S, Ingelheim, Germany), 1-methyl-2-pyrrolidinone 
(NMP) and ethanol absolute 99.8+% was purchased from Acros Organics (Geel, Belgium); NMP was 
reagent grade and PLGA was GMP grade and ethanol was GLC grade. ACN and acetic acid were 
purchased from Sigma-Aldrich, UK. Simvastatin was purchased from Johnson and Johnson.  
Simvastatin was used in its unmodified form, with the lactone ring intact, and dissolved in the 
membrane casting dope for diffusion-dependent release; for degradation-dependent release, 
simvastatin was saponified (Figure 1) then added to the membrane casting dope for covalent bonding 
to the PLGA. The scaffold preparation is described below for both the dissolved simvastatin (dis-sim) 
and the saponifiedsimvastatin (sap-sim). 
Figure 1. Chemical structure of simvastatin with the closedlactone ring prior to- and open 
lactone ring after the process of saponification. 
simvastatin Saponifiedsimvastatin 
 
2.2. Extraction and Saponification of Simvastatin 
10 mg simvastatin tablets were saponified using a methoddeveloped by Whang et al. [19]; a mixture 
of EtOH extracted solution of simvastatin with 0.1 N sodium hydroxide (NaOH) was heated 
at 50 °C for two hours.  
2.3. Membrane Scaffold Preparation 
The PLGA membrane casting dope was prepared from PLGA and NMP in a 20% (w/w) polymer 
solution. For diffusion-controlled release, dis-sim was dissolved in the casting dope at concentration  
of 1 mg simvastatin per g PLGA (mg/g). For degradation-controlled release, sap-sim at two different 
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concentrations of 0.5 mg/g and 1 mg/g were dissolved in the casting dope. Flat-sheet membrane 
scaffolds were prepared by solvent exchange with distilled water as described elsewhere [26,27].  
2.4. Simvastatin Quantification by HPLC 
HPLC analysis was carried on a Shimadzu LC-10A series system (Kyoto, Japan) equipped with a 
Phenomenex AQUA C18 reverse phase column (150 mm  4.6 mm, 5 mm; Torrance, USA). A 
mixture of filtered and degassed ACN:H20 + 0.1% Acetic acid (60:40 v/v) was used as mobile phase 
and flow rate of 1.0 mL/min at max UV absorption of 248 nm. In order to evaluate the kinetics of 
drug-release, samples were taken from the air-dried membranes and soaked in absolute EtOH to 
facilitate degradation of membrane. 
2.5. Viscosity of the PLGA Membrane Casting Dopes 
The viscosity of the PLGA membrane casting dopes was measured using a plate and cone 
rheometer (BohlinRheometer CS, BohlinReologi, Sjöbo, Sweden) at a constant temperature of 20 °C. 
2.6. Morphology of PLGA Membrane Scaffolds 
The morphology of the simvastatin-free, dis-sim and sap-sim PLGA flat sheet membranes was 
studied using scanning electron microscopy (SEM) after 3 days in deionised water to remove residual 
solvent. Samples were dried before preparation for SEM. A thin layer of gold coating was deposited on 
the sample before observation with the SEM microscope (JSM6310, JEOL, Herts, UK) after sputtering 
with gold (5150B sputter coater, BOC Edwards, West Sussex, UK). 
3. Results and Discussion 
The overall objective of this study was to investigate techniques to incorporate simvastatin into 
PLGA membrane scaffolds and the resulting effects on the membrane properties and the release 
mechanism, to develop new membrane scaffolds to be used for bone tissue engineering purposes.  
In a new approach, simvastatin was incorporated into PLGA flat sheet membrane scaffolds by 
adding either the unmodified drug (dis-sim), or saponifiedsimvastatin (sap-sim) to the PLGA 
membrane casting dope. Molecular weight and polymer chain structure are recognized as important 
factors governing polymer properties [18] and therefore characteristics such as the solution properties 
of the membrane casting dope, thermodynamic interactions with the solvent and non-solvent, and 
physical behaviour during casting which in turn determine the final membrane structure. 
3.1. Viscosity of the Casting Dopes Was Reduced on Addition of Sap-Sim 
To evaluate the effect of simvastatin on the rheology of the PLGA membrane casting dopes, 
viscosity measurements were taken before and after introduction of either dis-sim or sap-sim, the 
values of which are shown in Table 1. A significant reduction in the viscosity of the membrane casting 
dope was seen when sap-sim dopes were compared to the drug-free dopes. Furthermore, a proportional 
relationship between viscosity of sap-sim dopes to the concentration of simvastatin in the dopes was 
observed. Drug-free dopes had a viscosity of 1.2 Pa s and an increase in sap-sim from 0.5 mg/g to 1 mg/g 
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caused a reduction in viscosity from 0.2 Pa s to 0.05 Pa s. The addition of dis-sim to the membrane 
casting dope did not have an effect on the viscosity which remained at 1.2 Pa s.  
Table 1. Viscosities of membrane casting dopes. 
Dope Composition PLGA 
PLGA + Dis-Sim 
(1.0 mg sim/g 
PLGA) 
PLGA + sap-sim 
(0.5 mg sim/g 
PLGA) 
PLGA + sap-sim 
(1.0 mg sim/g 
PLGA) 
Viscosity (Pa s) 1.2 1.2 0.21 0.05 
3.2. Covalent Bonding of Sap-Sim to PLGA Appears to Increase Porosity of Membranes 
Scanning electron microscopy analysis revealed no difference in the PLGA membrane surface 
morphology when they were cast using drug-free casting dopes [Figure 2(A)] or dis-sim casting dopes 
[(Figure 2(B)]. With increasingaddition of sap-sim, an increase in the number and size of surface pores 
were observed [Figure 2(C,D)]. It was also observed that the increase in sap-sim gradually changed the 
PLGA membrane from flexible to brittle.  
Figure 2. Surface morphology of PLGA membranes with different simvastatin preparations. 
(A) PLGA only, (B) PLGA + dis-sim (1.0 mg sim/g PLGA), (C) PLGA + sap-sim  
(0.5 mg Sim/g PLGA), (D) PLGA + sap-sim (1.0 mg Sim/g PLGA) 3 days after 
detoxification in water. 
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3.3. Simvastatin Release Mechanisms Are Different for Dis-Sim and Sap-Sim 
The results showed a decrease in statin concentration in the membrane, from 0.9 g/mL at 48 h  
to 0.5 g/mL at 96 h (Figure 3). There was no significant difference between the release profiles for 
the 0.5 mg/g and 1.0 mg/g sap-sim membranes, and there was no significant difference in release rate 
over the 4 days, with values remaining between 0.3 and 0.4 g/mL. 
Figure 3. Simvastatin net release-profiles. Samples of membrane were dried and the 
simvastatin extracted then quantified by HPLC, and relative concentrations calculated from 
a calibration curve (not shown); n = 6. 
 
 
The decrease in viscosity of the casting dope and the increase in porosity and pore size that was 
observed on the addition of sap-sim can be attributed to either cleavage of PLGA ester bonds or a 
change in polymer chain structure due to the covalent bonding of the sap-sim, or a combination of 
both. The proposed mechanism for covalent bonding to the PLGA via cleavage of the ester bonds is 
shown in Figure 4. 
The observation that there was no difference between the different concentrations of sap-sim is not 
surprising. The active statin is covalently bound to the PLGA membrane and thus there are two 
mechanisms to be considered in the release of the drug. There is the reaction required to release the 
statin, followed by diffusion of the statin to the bulk solution. It is likely that that there is a change in 
the controlling mechanism with release time, moving from reaction control initially, to diffusion 
control at later times. The diffusion of statin to the bulk solution will be dependent on the free 
concentration of statin in the bulk solution, and it is likely that this becomes limiting at relatively low 
concentrations. In contrast, the dis-sap membrane exhibited a typical diffusion-dependant pattern of 
drug release. 
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Figure 4. Schematic of proposed mechanism of PLGA ester bond cleavage in presence of 
saponifiedsimvastatin and subsequent covalent bonding of PLGA and saponifiedsimvastatin. 
 
4. Conclusions 
Simvastatin can be incorporated into PLGA membrane scaffolds by adding the drug into the casting 
dope. The release kinetics were shown to be dependent on the form of simvastatin and its interaction 
with PLGA on addition to the membrane casting dope. This study showed that simvastatincan be 
successfully incorporated into PLGA membrane scaffolds for controlled release of the drug into the 
bone microenvironment. 
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